Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$194.15 USD

194.15
3,179,012

-1.30 (-0.67%)

Updated Oct 4, 2024 03:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AbCellera (ABCL) to Develop New Antibody Therapies With AbbVie

by Zacks Equity Research

AbCellera (ABCL) inks a strategic collaboration with AbbVie to develop new antibody therapies across multiple indications. ABCL shares rise.

AbbVie (ABBV) Gains As Market Dips: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed the most recent trading day at $164.86, moving +0.04% from the previous trading session.

Kinjel Shah headshot

Pharma Stock Roundup: SNY, GSK, PFE Relieved on Zantac Win & Other Updates

by Kinjel Shah

A U.S. district court dismisses thousands of lawsuits involving Zantac, which spells relief for GSK (GSK), Sanofi (SNY) and Pfizer (PFE). Pfizer and AbbVie (ABBV) announce new research collaborations.

AbbVie (ABBV) Gains But Lags Market: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed at $165.99 in the latest trading session, marking a +0.36% move from the prior day.

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Derek Lewis headshot

Relative Strength Found Within These 3 Medical Stocks

by Derek Lewis

The Zacks Medical sector has modestly outperformed the S&P 500 over the last three months, up more than 7% vs. the general market's 4% gain.

Why Is Pfizer (PFE) Up 6.5% Since Last Earnings Report?

by Zacks Equity Research

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for HDV

Neena Mishra headshot

2 High Income ETFs Crushing the S&P 500

by Neena Mishra

These ETFs use option strategies to generate juicy income & lower portfolio volatility

Here's What's Driving AbbVie's (ABBV) Outperformance This Year

by Zacks Equity Research

AbbVie (ABBV) boasts several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.

Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know

by Zacks Equity Research

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Kinjel Shah headshot

Pharma Stock Roundup: MRK to Buy IMGO, ABBV's Skyrizi Gets EU Nod for New Indication

by Kinjel Shah

Merck (MRK) offers to buy Imago Biosciences (IMGO). The European Commission approves AbbVie's (ABBV) immunology medicine, Skyrizi for Crohn's disease.

AbbVie's (ABBV) Skyrizi Gets EU Nod for Crohn's Disease

by Zacks Equity Research

AbbVie's (ABBV) Skyrizi becomes the first specific IL-23 inhibitor to get approval for Crohn's disease in the European Union.

The Zacks Analyst Blog Highlights AbbVie PepsiCo, The Walt Disney, Caterpillar and PBF Energy

by Zacks Equity Research

AbbVie, PepsiCo, The Walt Disney, Caterpillar and PBF Energy are part of The Zacks top Analyst Blog.

Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for HDV

Sheraz Mian headshot

Top Stock Reports for AbbVie, PepsiCo & Walt Disney

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), PepsiCo, Inc. (PEP) and The Walt Disney Company (DIS).

AbbVie (ABBV) BLA for Epcoritamab Gets FDA Priority Tag

by Zacks Equity Research

The FDA grants priority review status to AbbVie's (ABBV) BLA for epcoritamab for the relapsed/refractory large B-cell lymphoma (LBCL), a form of NHL.

CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron

by Zacks Equity Research

CytomX (CTMX) gets a boost after its deal with Regeneron for the development of investigational next-generation bispecific immunotherapies.

Key Factors Driving Amgen's (AMGN) Outperformance This Year

by Zacks Equity Research

Amgen's (AMGN) key drugs like Prolia, Repatha and Otezla are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.

Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FDL

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Derek Lewis headshot

3 Dividend Kings Crushing the S&P 500 in 2022

by Derek Lewis

Companies in the Dividend King club carry well-established and successful business operations, clearly displayed by their commendable commitment to shareholders over decades of increased dividend payouts.

Ironwood's (IRWD) Q3 Earnings Beat, Linzess Volume Grows

by Zacks Equity Research

Ironwood (IRWD) beat earnings estimates in the third quarter. Sales, though missing estimates, rose year over year. Stock up.

Amgen (AMGN) Beats on Q3 Earnings & Sales, Tweaks 2022 View

by Zacks Equity Research

Amgen (AMGN) beats Q3 estimates for earnings and sales. It tightens previously issued revenue and adjusted earnings guidance ranges.

    5 Stocks to Watch on Recent Dividend Hikes Amid High Volatility

    by Zacks Equity Research

    Investors may keep a tab on ABBV, ASTE, BCC, ESQ and HIG, which have lately hiked their dividend payments to reward investors.